Lead sponsor
Merck Sharp & Dohme LLC
26 Alzheimer’s disease and related dementias trials led. Source: ClinicalTrials.gov, as of July 21, 2026.
26
Trials led
1
Ongoing
6,201
Total enrollment
210
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1
15
Phase 2
8
Phase 2/3
1
Phase 3
2
Trials by status
Recruiting
1
Completed
17
Terminated
7
Withdrawn
1
Trials led
TrialEligibility highlightPhaseStatusEnrollment
Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED)Alzheimer's diseasePh 2Completed512
A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)mild-to-moderate ADPh 2Terminated369
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)Alzheimer's diseasePh 2Recruiting340
Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Participants With Alzheimer's Disease (MK-4305-061)Alzheimer's diseasePh 3Completed285
Efficacy and Safety of MK-7622 as Adjunct Therapy in Participants With Alzheimer's Disease (MK-7622-012)Alzheimer's diseasePh 2Terminated240
MK0249 for the Symptomatic Treatment of Alzheimer's Disease (MK0249-011)mild-to-moderate ADPh 2Completed144
A Study to Test the Performance of the CogState Computerized Neuropsychological Battery in Patients With Alzheimer's Disease (0000-086)(COMPLETED)Study partner/caregiver requiredPh 1Completed106
Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008)mild-to-moderate AD / moderate AD dementiaPh 2Terminated99
Cognition Platform Study in Participants at Risk for Alzheimer's Disease (AD) (MK-0000-413)Alzheimer's diseasePh 1Completed44
Computerized Cognition Testing in Participants With Mild Alzheimer's Disease (AD) Treated With Donepezil (MK-0000-318)Alzheimer's diseasePh 2Completed36
A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002)mild-to-moderate ADPh 1Completed34
BOLD Functional Magnetic Resonance Imaging (fMRI) and Cerebral Blood Flow Measurements as Biomarkers for Cognition Enhancing Drugs (3134-006)Age 18-45Ph 1Completed32
A Study of the Safety, Tolerability, and Pharmacodynamics of MK-8931 in Participants With Alzheimer's Disease (MK-8931-010 AM1 [P07820 AM1])mild-to-moderate ADPh 1Completed32
Elpipodect (MK-8189) Safety and Tolerability in Participants With Alzheimer's Disease With or Without Symptoms of Agitation-Aggression and/or Psychosis (MK-8189-017)Alzheimer's diseasePh 1Completed29
Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007)Alzheimer's diseasePh 1Completed28
EEG (Electroencephalogram) Platform Standardization in Healthy Male Subjects (3134-010)Age 18-40Ph 1Completed25
MK0952 in Patients With Mild-to-Moderate Alzheimer's Disease (0952-004)(COMPLETED)mild-to-moderate ADPh 2Terminated24
An Open-Label Study Investigating MK-8931 in Participants With Mild and Moderate Hepatic Insufficiency (MK-8931-016)Age 45-85Ph 1Completed16
A Study to Evaluate the Effects of Itraconazole on MK-1708 in Healthy Participants (MK-1708-003)Age 18-50Ph 1Completed12
A Two-Part, Single-Dose Study of the Pharmacokinetics of MK-8931 in Subjects With Renal Insufficiency (MK-8931-009 [P08535])Healthy volunteersPh 1Completed12
A Study to Evaluate the Effects of MK-0249 and an Alzheimer's Disease Medication on Cognitive Function in Adults With Alzheimer's Disease (MK-0249-023)mild-to-moderate ADPh 1Terminated4
Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)mild AD dementiaPh 1Withdrawnnot disclosed